Download Free Sample Report

The global PD-1 and PD-L1 Drug market was valued at US$ 24.3 billion in 2023 and is projected to reach US$ 48.5 billion by 2030, at a CAGR of 10.1% during the forecast period. 

The USA market for Global PD-1 and PD-L1 Drug market is estimated to increase from USD million in 2023 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.

The China market for Global PD-1 and PD-L1 Drug market is estimated to increase from USD million in 2023 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.

The Europe market for Global PD-1 and PD-L1 Drug market is estimated to increase from USD million in 2023 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.

The U.S. Market is Estimated at $ Million in 2023, While China is Forecast to Reach $ Million.
PD-1 Monoclonal Antibody Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of PD-1 and PD-L1 Drug include Bristol Myers Squibb, Merck & Co., Inc., F. Hoffmann -La Roche Ltd, AstraZeneca, Sanofi, Pfizer Inc, Lilly, Novartis AG and GSK, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
PD-1/PD-L1 is an important part of the human immune system-a drug target on T cells. Drugs designed for this target can activate the immune effect of T cells on tumor cells, thereby awakening the patient's own anti-cancer effect. tumor effect.
This report aims to provide a comprehensive presentation of the global market for PD-1 and PD-L1 Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-1 and PD-L1 Drug. This report contains market size and forecasts of PD-1 and PD-L1 Drug in global, including the following market information:

• Global PD-1 and PD-L1 Drug Market Revenue, 2019-2024, 2025-2030, ($ millions)
• Global PD-1 and PD-L1 Drug Market Sales, 2019-2024, 2025-2030, (K Units)
• Global top five PD-1 and PD-L1 Drug companies in 2023 (%)

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the PD-1 and PD-L1 Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global PD-1 and PD-L1 Drug Market, by Type, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global PD-1 and PD-L1 Drug Market Segment Percentages, by Type, 2023 (%)

• PD-1 Monoclonal Antibody
• PD-L1 Monoclonal Antibody

Global PD-1 and PD-L1 Drug Market, by Application, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global PD-1 and PD-L1 Drug Market Segment Percentages, by Application, 2023 (%)

• Liver Cancer
• Esophageal Cancer
• Nasal Cancer
• Stomach Cancer
• Other

Global PD-1 and PD-L1 Drug Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global PD-1 and PD-L1 Drug Market Segment Percentages, By Region and Country, 2023 (%)

• North America (United States, Canada, Mexico)
• Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
• Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
• The Middle East and Africa (Middle East, Africa)
• South and Central America (Brazil, Argentina, Rest of SCA)

Competitor Analysis
The report also provides analysis of leading market participants including:

• Key companies PD-1 and PD-L1 Drug revenues in global market, 2019-2024 (Estimated), ($ millions)
• Key companies PD-1 and PD-L1 Drug revenues share in global market, 2023 (%)
• Key companies PD-1 and PD-L1 Drug sales in global market, 2019-2024 (Estimated), (K Units)
• Key companies PD-1 and PD-L1 Drug sales share in global market, 2023 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Bristol Myers Squibb
• Merck & Co., Inc.
• F. Hoffmann -La Roche Ltd
• AstraZeneca
• Sanofi
• Pfizer Inc
• Lilly
• Novartis AG
• GSK
• Junshi Biosciences
• Akeso, Inc
• BeiGene
• Innovent
• Jiangsu Hengrui Medicine Co.,Ltd
• Cstone
• Henlius
• Simcere Pharmaceutical Group Limited

Outline of Major Chapters:
Chapter 1: Introduces the definition of PD-1 and PD-L1 Drug, market overview.
Chapter 2: Global PD-1 and PD-L1 Drug market size in revenue and volume.
Chapter 3: Detailed analysis of PD-1 and PD-L1 Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of PD-1 and PD-L1 Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global PD-1 and PD-L1 Drug capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.